Cytori Therapeutics, Inc. (USA) (NASDAQ:CYTX)

CAPS Rating: 2 out of 5

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.

Recs

0
Player Avatar bIlluminati (31.17) Submitted: 9/27/2012 9:09:14 PM : Underperform Start Price: $4.40 CYTX Score: +10.47

It's broke, its main partner is nearly broke, and isn't near any product.

Featured Broker Partners


Advertisement